# Felix Biotechnology

backed by the Cystic Fibrosis Foundation, is running the Yale-based CYPHY Phase 1/2 trial of YPT-01 against chronic P. aeruginosa lung infection in CF patients — a chronic, biofilm-forming indication where conventional antibiotics manage but rarely clear infection.


Source: https://cn.bioecon.ru/companies/felix-biotechnology/
Updated: 2026-08-09

- 国家: United States

## 技术

- [噬菌体疗法](https://cn.bioecon.ru/technology/bacteriophage-therapy/)